Britain and America have secured a landmark bilateral deal that will maintain zero duties on British pharmaceutical shipments entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This move ensures that duties on these crucial goods will be held at zero for a period of three years.
This agreement comes after earlier threats to significantly raise tariffs on patented pharmaceutical products, with figures discussed up to one hundred percent.
"This arrangement between the Britain reinforces the global environment for cutting-edge drugs and introduces much-needed equity to transatlantic drug exports," a statement noted.
Commercial Impact
Drugs represent one of the UK's most significant export categories to the US, which is by far the biggest market for major British pharmaceutical firms.
Trade data show that in the one-year period leading up to last September, the UK exported drugs worth £11.1bn to the US. This amount accounted for 17.4% of British export trade in that period.
"This guarantee safeguards work, stimulates investment and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage manufacturers must return to the NHS to control costs will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The deal follows a long-running row between the sector and the UK government over drug pricing and approval rates.
These tensions were heightened by arguments that US patients were charged several times more for the same drugs than consumers in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or cancelled, while major expansions have been announced toward US facilities.
One official publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
